AlloDx to Showcase Three Innovative Assay Kits at ASN Kidney Week 2026

From capturing low-abundance autoantibodies and recognizing complement activation-specific epitopes to advancing quantitative assays with monoclonal antibody standards, kidney immunology research places increasing demands on assay technology: detecting and interpreting signals, while establishing a basis for comparable measurements.

On October 22–24, 2026, AlloDx will present three key assay kits — anti-Nephrin autoantibody, sC5b-9 and C3NeF — at the ASN Kidney Week 2026 scientific exhibition in Denver, USA. Welcome to Colorado Convention Center, Hall A, Booth 991, to explore advances in kidney immune testing and research collaboration with the AlloDx team.

Building on its in-house assay methods and core antibody development, AlloDx serves advanced kidney research and specialist testing markets worldwide, focusing on recognition specificity, low-abundance detection and quantitative standardization across key measurement steps.

Join us at
Colorado Convention Center
Hall A · Booth 991

AlloDx ASN 2026 booth design rendering

C3NeF: Advancing Quantitative Measurement with Recombinant Monoclonal Antibody Calibration

Further development of C3NeF assays requires a defined calibration relationship between assay signals and quantitative results. At this exhibition, AlloDx will highlight research into a quantitative magnetic bead assay using a recombinant C3NeF monoclonal antibody as the standard.

The method uses C3b-coupled magnetic beads as the reaction support. Background is controlled by subtracting signals between test and control wells; anti-human IgG then detects binding, and sample results are calculated using a monoclonal antibody standard curve. The monoclonal antibody standard provides a defined, reproducible source of calibration and a methodological basis for subsequent batch control and comparisons across research results.

The C3NeF testing technology independently developed by AlloDx achieves a serial calibration range of 18.75–1200 ng/mL and has conducted validation around reference standards, curve calibration, and sample measurement, to advance C3NeF testing toward more standardized quantification.

Meanwhile, the R&D system is also exploring the use of Bb retention on magnetic beads to assess convertase stabilization. The IgG-binding readout and the Bb-retention readout provide complementary immune-binding and functional information. The current standard curve corresponds to the indirect IgG method; the two readouts remain distinct in methodology and result interpretation.

From standards to assay systems and from binding signals to function-related readouts, AlloDx focuses on developing measurement tools that support more informative interpretation in C3NeF research.

sC5b-9: AD99 Recognizes a C9 Neoepitope

A key aspect of measuring terminal complement activation is recognizing structural features that emerge after complex formation. At the core of the AlloDx sC5b-9 assay kit is the AD99 monoclonal antibody, which targets a conformational neoepitope of polymerized C9.

According to AlloDx research and development materials, the AD99 target epitope is formed jointly by adjacent C9 subunits at their conformational interface. This design focuses recognition on structural changes arising from complex assembly, rather than simply identifying an individual complement component.

In the two-antibody sandwich ELISA, AD99 serves as the capture antibody, while the detection antibody recognizes C5b. The paired readout targets distinct structural sites, placing the molecular structure being recognized at the center of assay design.

For AlloDx, core antibody development spans target epitope selection, antibody screening and assay construction. Based on AD99, the sC5b-9 product is intended for research into terminal complement activation, providing a measurement tool for studies of kidney disease mechanisms and complement interventions.

SuperNAT: Improving the Resolution of Low-Abundance Signals

Anti-Nephrin autoantibodies offer a new perspective in research on podocyte-associated diseases. To address low-abundance targets and complex sample backgrounds, SuperNAT (Super Nephrin Antibody Trap) combines magnetic bead capture, enrichment and washing, and background subtraction in a workflow designed to resolve target signals more clearly.

Magnetic-bead capture and enrichment:Through antigen–antibody binding and magnetic separation, target antibodies are concentrated into a detectable reaction system, providing methodological support for low-abundance antibody detection.

Background subtraction and interference control:Background correction is incorporated into the readout workflow; existing R&D data also include interference assessments under hemolyzed and high-triglyceride sample conditions, reflecting the complexity of real-world samples.

Reproducibility and longitudinal research:The data report an intra-run CV of 6.8% and an inter-run CV of 10.4%, providing preliminary support for repeated measurements under the tested conditions. Longitudinal studies of antibody level changes will help further explore their relationship with disease phenotype and course.

SuperNAT detects anti-Nephrin autoantibodies. Through clearer target recognition and a more consistent assay workflow, AlloDx aims to support research into minimal change disease and related podocyte disorders, helping translate emerging biological discoveries into measurable and verifiable research practice.

Gathering at ASN Kidney Week 2026

The three products reflect AlloDx's sustained commitment to kidney immune testing: SuperNAT improves signal discrimination for low-abundance autoantibodies, AD99 targets neoepitopes of complement complexes, and recombinant monoclonal calibration advances quantitative C3NeF testing.

To address the needs of advanced research worldwide, AlloDx looks forward to discussions with nephrology experts, research institutions and specialist partners on methodological validation, clinical sample studies and international collaboration.

October 22–24, 2026 · Denver, USA. AlloDx looks forward to welcoming you at Hall A · Booth 991.